Degrasyn

TargetMol
Product Code: TAR-T6300
Supplier: TargetMol
CodeSizePrice
TAR-T6300-5mg5mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6300-1mL1 mL * 10 mM (in DMSO)£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6300-10mg10mg£153.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6300-25mg25mg£238.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6300-50mg50mg£373.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6300-100mg100mg£519.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Degrasyn (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).
CAS:
856243-80-6
Formula:
C19H18BrN3O
Molecular Weight:
384.277
Pathway:
Autophagy; Tyrosine Kinase/Adaptors; Cytoskeletal Signaling; Ubiquitination; Angiogenesis; Apoptosis; DNA Damage/DNA Repair; Cell Cycle/Checkpoint
Purity:
0.9998
SMILES:
CCC[C@H](NC(=O)C(=Cc1cccc(Br)n1)C#N)c1ccccc1
Target:
Apoptosis; Bcr-Abl; DUB; Autophagy

References

Yan B, Guo J, Wang Z, et al.The ubiquitin?specific protease 5 mediated deubiquitination of LSH links metabolic regulation of ferroptosis to hepatocellular carcinoma progression.MedComm.2023, 4(4): e337. Bartholomeusz GA, et al. Blood, 2007, 109(8), 3470-3478. Kapuria V, et al. Cancer Res, 2010, 70(22), 9265-9276. Luo H, Jing B, Xia Y, et al. WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia[J]. Cancer Cell International. 2019 Mar 13;19:56. Luo H, Jing B, Xia Y, et al. WP1130 reveals USP24 as a novel target in T-cell acute lymphoblastic leukemia. Cancer Cell International. 2019 Mar 13;19:56 Bartholomeusz G, et al. Cancer Res, 2007, 67(8), 3912-3918.